PYC Therapeutics Limited (AU:PYC)
Australian Market

PYC Therapeutics Limited (PYC) Income Statement


PYC Therapeutics Limited Income Statement

Last quarter (Q4 2022), PYC Therapeutics Limited's total revenue was AU$―, a decrease of ― from the same quarter last year. In Q4, PYC Therapeutics Limited's net income was AU$―. See PYC Therapeutics Limited’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Jun 22Jun 21Jun 20Jun 19Jun 18
Total Revenue
Cost of Revenue
Gross Profit
Operating Expense
-AU$ 30.21MAU$ 21.83MAU$ 9.74MAU$ 7.10MAU$ 9.77M
Operating Income
-AU$ -30.21MAU$ -21.83MAU$ -9.74MAU$ -7.10MAU$ -9.77M
Net Non Operating Interest Income Expense
-AU$ -8.17KAU$ 69.68KAU$ 207.03KAU$ 117.96KAU$ 114.88K
Other Income Expense
-AU$ 15.92MAU$ 3.13MAU$ 62.50KAU$ 250.00AU$ 48.46K
Pretax Income
-AU$ -14.29MAU$ -18.63MAU$ -9.48MAU$ -6.98MAU$ -9.60M
Tax Provision
-AU$ 0.00AU$ 0.00AU$ -2.40MAU$ -2.90MAU$ -2.17M
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
-AU$ -13.86MAU$ -17.77MAU$ -6.82MAU$ -4.08MAU$ -7.43M
Basic EPS
-AU$ >-0.01AU$ >-0.01AU$ >-0.01AU$ >-0.01-
Diluted EPS
-AU$ >-0.01AU$ >-0.01AU$ >-0.01AU$ >-0.01-
Basic Average Shares
-AU$ 3.18BAU$ 3.09BAU$ 2.64BAU$ 2.40B-
Diluted Average Shares
-AU$ 3.18BAU$ 3.09BAU$ 2.64BAU$ 2.40B-
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
Net Income From Continuing And Discontinued Operation
-AU$ -13.86MAU$ -17.77MAU$ -6.82MAU$ -4.08MAU$ -7.43M
Normalized Income
-AU$ -13.86MAU$ -17.77MAU$ -6.82MAU$ -4.08MAU$ -7.43M
Interest Expense
-AU$ 32.59KAU$ 38.82K---
-AU$ -14.26MAU$ -18.59MAU$ -9.74MAU$ -7.10MAU$ -9.77M
-AU$ -13.42MAU$ -17.97MAU$ -9.20MAU$ -6.97MAU$ -9.69M
Currency in AUD

PYC Therapeutics Limited Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis